NCT00741377 |
|
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
|
View
|
NCT02013154 |
|
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
|
View
|
NCT05761951 |
|
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 DKK1 Inhibitor Leap Therapeutics and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
|
View
|
NCT04329351 |
|
Impact of PTFE-d Barrier Intentionally Exposed to Bucal Environment in Guided Bone Regeneration to Ridge Preservation
|
View
|
NCT02708368 |
|
SOPs for CKD-MBD-Biomarkers
|
View
|
NCT01431872 |
|
Systemic Dickkopf-related Protein 1 DKK1During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors
|
View
|
NCT01711671 |
|
A Study of DKN-01 and LenalidomideDexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
|
View
|
NCT05480306 |
|
Phase 2 Study of DKN-01 in Colorectal Cancer
|
View
|
NCT02375880 |
|
Study of DKN-01 and GemcitabineCisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
|
View
|
NCT03591614 |
|
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
|
View
|
NCT03395080 |
|
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
|
View
|
NCT04363801 |
|
A Study of DKN-01 in Combination With Tislelizumab Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
|
View
|
NCT04681248 |
|
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
|
View
|
NCT01302886 |
|
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
|
View
|
NCT01337752 |
|
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
|
View
|
NCT02212262 |
|
Role of Osteocytes in Myeloma Bone Disease
|
View
|
NCT03837353 |
|
A Parallel Arm Phase 1b2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
|
View
|